
Gan & Lee Reports Positive Phase III Data for Insulin and Weight Loss Drugs
Gan & Lee Pharmaceuticals has reached key milestones in its metabolic disease pipeline, as its once-weekly insulin candidate Ludefen and the weight loss injection bofanglutide both hit primary endpoints in late-stage clinical trials across China and the United States.

























